The company's portfolio includes promising drug candidates, such as the CD40 agonist mitazalimab, and it is also involved in co-developing projects with other companies. Alligator's technology platform utilizes proprietary technologies, ALLIGATOR-GOLD® and FIND®, which enable the optimization of antibodies and other proteins. Their focus is on immunotherapy for cancer treatment, aiming to improve the immune system's ability to fight cancer cells and block the defense mechanisms used by tumors. Alligator Bioscience discovers and develops antibody-based immunotherapies, with a pipeline that currently includes three immune-modulating projects.